Hong Kong-listed biopharma company Alphamab Oncology reported the repurchase of 312,000 ordinary shares on 6 November 2026, acquiring the stock on the Hong Kong Stock Exchange at prices ranging from HKD 6.22 to HKD 6.38 per share. The transaction cost totalled HKD 1.97 million, implying a volume-weighted average price of HKD 6.32 per share.

Following the buyback, Alphamab’s issued share capital (excluding treasury shares) fell 0.03% to 965.39 million shares, while treasury shares increased to 8.99 million. The company’s total issued share count, including treasury stock, remained unchanged at 974.38 million shares, as the repurchased shares are being held in treasury rather than cancelled.

The repurchase formed part of a mandate approved on 12 June 2026 authorising the company to buy back up to 96.85 million shares. Cumulative purchases under this mandate have reached 3.11 million shares, equivalent to 0.32% of the company’s issued share base at the mandate date.

In accordance with Hong Kong Stock Exchange regulations, Alphamab Oncology is subject to a moratorium on issuing new shares or transferring treasury shares until 6 December 2026. All buybacks were executed in compliance with the Exchange’s Main Board Rules, and no material changes to the company’s previously filed explanatory statement were reported.